SNSW(SH:688117) Ge Long Hui·2026-02-11 07:55Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement for the first to eighth batches of drugs, marking the first nationwide unified continuation of centralized procurement for chemical drugs [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., is involved in the new round of continuation procurement organized by the state [1] - The continuation procurement includes the company’s products such as Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch) [1] Group 2: Market Impact - The selected products will be prioritized for use by medical institutions during the procurement period, ensuring the completion of the agreed procurement volume [1] - The selection in this continuation procurement reflects the stability and reliability of the company’s drug quality, which is expected to expand the sales scale of the selected products and increase market share [1] - This development is anticipated to strengthen the company’s competitiveness in the peptide pharmaceutical market and positively impact its operational growth [1]